drugset / Trial / NCT06932146
A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2a study of glycolate oxidase inhibitor LLX-424 in patients with a history of kidney stones. Eligible subjects with a history of kidney stones will be randomized to receive study drug (LLX-424 or placebo) for 8 weeks.
Timeline
- Start
- 2025-03-23
- Primary completion
- 2025-09-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LLX-424 | Unknown | — | Oral |